We are live on ! Find out more
AGP

Artia Global Partners Portfolio holdings

AUM $542M
1-Year Est. Return 206.64%
This Fund
S&P 500
This Quarter Est. Return
+81.78%
1 Year Est. Return
+206.64%
3 Year Est. Return
+724.84%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$631M
AUM Growth
+$215M
Cap. Flow
+$61.2M
Cap. Flow %
9.7%
Top 10 Hldgs %
69.95%
Holding
56
New
19
Increased
12
Reduced
4
Closed
5

Top Buys

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$21.2M
2
UGL icon
ProShares Ultra Gold
UGL
+$20.2M
3
ABVX
Abivax
ABVX
+$13.8M
4
SLNO
Soleno Therapeutics
SLNO
+$13.2M
5
QURE icon
uniQure
QURE
+$12M

Top Sells

Rank Stock Value
1
VRNA
Verona Pharma
VRNA
+$56.9M
2
SWTX
SpringWorks Therapeutics
SWTX
+$3M
3
INSM icon
Insmed
INSM
+$2.51M
4
LLY icon
Eli Lilly
LLY
+$1.49M
5
SRRK icon
Scholar Rock
SRRK
+$1.05M

Sector Composition

Rank Sector Weight
1 Healthcare 85.92%
2 Miscellaneous 13.84%
3 Financials 0.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRRK icon
26
Scholar Rock
SRRK
$6.99B
$3.59M 0.57%
96,285
-30,000
-24% -$1.05M
ABBV icon
27
AbbVie
ABBV
$440B
$3.36M 0.53%
14,500
– –
NKTR icon
28
Nektar Therapeutics
NKTR
$2.58B
$3.3M 0.52%
+57,999
New +$1.92M
CNTA
29
DELISTED
Centessa Pharmaceuticals
CNTA
$3.23M 0.51%
+133,291
New +$2.37M
ASND icon
30
Ascendis Pharma A/S
ASND
$17.7B
$2.43M 0.39%
12,240
– –
MLYS icon
31
Mineralys Therapeutics
MLYS
$2.75B
$2.15M 0.34%
56,600
+15,500
+38% +$335K
UTHR icon
32
United Therapeutics
UTHR
$21.4B
$2.1M 0.33%
5,000
– –
TGTX icon
33
TG Therapeutics
TGTX
$8.53B
$1.97M 0.31%
54,515
– –
RARE icon
34
Ultragenyx Pharmaceutical
RARE
$1.47B
$1.94M 0.31%
64,502
+22,672
+54% +$680K
RAPP
35
Rapport Therapeutics
RAPP
$2.21B
$1.92M 0.3%
+64,608
New +$1.15M
OCUL icon
36
Ocular Therapeutix
OCUL
$2.5B
$1.65M 0.26%
+141,061
New +$1.69M
XENE icon
37
Xenon Pharmaceuticals
XENE
$5.77B
$1.61M 0.25%
40,000
– –
IREN icon
38
Iris Energy
IREN
$18.5B
$1.56M 0.25%
+33,200
New +$806K
PTGX icon
39
Protagonist Therapeutics
PTGX
$9.44B
$1.52M 0.24%
22,951
– –
BTSG icon
40
BrightSpring Health Services
BTSG
$12.4B
$1.23M 0.19%
+41,600
New +$967K
BHVN icon
41
Biohaven
BHVN
$2.22B
$1.2M 0.19%
80,000
– –
KNSA icon
42
Kiniksa Pharmaceuticals
KNSA
$6.01B
$1.13M 0.18%
29,200
– –
BBIO icon
43
BridgeBio Pharma
BBIO
$14.6B
$1.06M 0.17%
+20,400
New +$995K
MREO
44
Mereo BioPharma
MREO
$40.7M
$979K 0.16%
475,361
– –
SRPT icon
45
Sarepta Therapeutics
SRPT
$2.21B
$865K 0.14%
+44,900
New +$800K
TVTX icon
46
Travere Therapeutics
TVTX
$6.23B
$739K 0.12%
30,900
– –
MRNA icon
47
Moderna
MRNA
$56B
$615K 0.1%
+23,800
New +$664K
KALV
48
DELISTED
KalVista Pharmaceuticals
KALV
$506K 0.08%
+41,555
New +$574K
ATYR
49
CALL
aTyr Pharma
ATYR
$47.2M
$433K 0.07%
+600,000
New +$2.72M
ATYR
50
aTyr Pharma
ATYR
$47.2M
$269K 0.04%
+372,276
New +$1.69M
1
2
3

Similar funds

CA
CV Advisors Aventura, Florida $542M AUM 24.89% 1-Year Est. Return
WCM
Westerly Capital Management San Francisco, California $542M AUM 48.48% 1-Year Est. Return
LI
Louisbourg Investments Dieppe, New Brunswick, Canada $542M AUM 21.44% 1-Year Est. Return
CWWM
Clear Wave Wealth Management Red Bank, New Jersey $541M AUM
FVCM
F&V Capital Management Boca Raton, Florida $542M AUM 46.38% 1-Year Est. Return
LI
Lafayette Investments Ashton, Maryland $542M AUM 22.5% 1-Year Est. Return
CCT
Chemung Canal Trust Elmira, New York $541M AUM 32.42% 1-Year Est. Return
MFS
Madrona Financial Services Everett, Washington $543M AUM 30.87% 1-Year Est. Return

Artia Global Partners's Q3 2025 Portfolio in Review

As of Q3 2025, Artia Global Partners held 56 positions worth $631M, up 52% from $416M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Artia Global Partners deployed $61.2M of net new capital in Q3 2025, opening 19 new positions and adding to 12 existing holdings. Its largest new stake was ProShares Ultra Gold: 537,372 shares worth $24.8M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 94% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Verona Pharma, an estimated $56.9M trimmed.

  • Artia Global Partners's largest Q3 2025 buy was ProShares Ultra Gold: 537,372 shares worth $24.8M.
  • Artia Global Partners added most to Vertex Pharmaceuticals in Q3 2025, an estimated $21.2M increase.
  • Artia Global Partners's biggest Q3 2025 reduction was Verona Pharma, cutting an estimated $56.9M.
  • Artia Global Partners fully exited SpringWorks Therapeutics in Q3 2025, selling an estimated $3M.
  • Artia Global Partners's ten largest holdings make up 70% of its $631M portfolio in Q3 2025.
  • Artia Global Partners opened 19 new positions and closed 5 in Q3 2025.
  • Artia Global Partners's portfolio value rose 52% quarter-over-quarter to $631M.

Based on Artia Global Partners's 13F filing for Q3 2025, filed 14 Nov 2025.